ClinicalTrials.Veeva

Menu

Role of OMT in the Management of the Persistent Post-COVID-19 Symptoms (ROMPS)

A

A.T. Still University of Health Sciences

Status

Completed

Conditions

Post-Acute COVID-19 Syndrome

Treatments

Procedure: osteopathic manipulative treatment (OMT)

Study type

Observational

Funder types

Other

Identifiers

NCT06016543
ROMPS-Pilot

Details and patient eligibility

About

The goal of this observational study is to determine the feasibility of conducting a large-scale study on the effect of using osteopathic manipulative treatment (OMT) to treat patients with post-COVID-19 symptoms. The main questions it aims to answer are:

  1. Is it feasible to conduct a large-scale study of the effect of OMT on patients with post-COVID-19 symptoms (based on how many patients agree to participate and how many complete the study)?
  2. How much change in patients' post-COVID-19 symptom severity, quality of life, and ability to return to work can we expect to see following OMT?

Participants will receive OMT as directed by their physician and complete questionnaires after every other OMT session.

  1. Participants will complete questionnaires about their post-COVID-19 symptoms, quality of life, ability to return to work, and adverse events they experienced 3 days after every other OMT session.
  2. Participants will be sent links to the questionnaires for 4 months or when their symptoms resolve, whichever comes first.
  3. Additionally, participants will complete a follow-up questionnaire 2 months after they stop receiving OMT for their post-COVID-19 symptoms or 6 months after enrollment in the study, whichever comes first.

Enrollment

7 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • at least one symptom of post-COVID-19 (eg, fatigue, dyspnea, anosmia, arthralgia, headache, sleep disturbances, anxiety/depression, or other problems related to mental health) which was new after diagnosis with COVID-19 and has persisted for at least 4 weeks after diagnosis

Exclusion criteria

  • unable to speak, read, and write in English
  • not mentally competent to give informed consent
  • inability to complete surveys/questionnaires online

Trial contacts and locations

1

Loading...

Central trial contact

Corey Luebbering, MPH; Jane C Johnson, MA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems